Core Insights - The article highlights that Konomai (Beijing) Technology Co., Ltd. completed a new round of strategic financing amounting to several tens of millions of RMB, funded exclusively by the Beijing Medical and Health Industry Investment Fund. The funds will be utilized for research and development iteration, capacity optimization, and market expansion [2]. Company Overview - Konomai was established on September 9, 2019, and is headquartered in Beijing. The company focuses on the research and production of ultra-high-performance liquid chromatography systems, specializing in high-end scientific instruments [3]. Products and Technology - The main products of the company include: - **Frontier Series**: Ultra-high-performance liquid chromatography systems designed for LC-MS applications, with a pressure tolerance of 22,000 PSI [6]. - **Leaps Series**: Includes two-dimensional liquid chromatography systems and bio-inert liquid chromatography systems tailored for various industry-specific needs [8]. - **EyouLab Intelligent Chromatography Data Management System**: A software solution for chromatographic data processing that complies with GMP and GLP requirements [10]. - The applications of these products span pharmaceuticals, biotechnology, food safety, academic research, and government testing, with market coverage extending to over 20 countries and regions globally [10]. Product Registration - The company has received several medical device registration certificates, including: - 5 types of quality control products for antipsychotic drug detection - 5 types of calibration products for antipsychotic drug detection - Liquid chromatography analyzers - 3 types of quality control products for antiepileptic drug detection - 3 types of calibration products for antiepileptic drug detection [12]. Financing History - Konomai's financing history includes: - February 10, 2026: A+ round, several tens of millions from Beijing Medical and Health Industry Investment Fund - August 19, 2025: A+ round, several tens of millions from Tianjin Jiuan Medical Electronics Co., Ltd. - June 5, 2023: A$2 round, approximately 100 million from multiple investors including Suzhou Huagai and Beijing Yuansheng Angel Investment [13]. Patent Information - The company holds several patents, including: - Control methods for column temperature boxes and temperature control systems - Automatic vent valves and methods for liquid chromatography instruments - Detection methods for coenzyme Q10 and its applications - Calibration methods for liquid chromatography pumps [15].

Core Insights - Chromai has completed a strategic financing round of several tens of millions of RMB, exclusively funded by the Beijing Pharmaceutical and Health Industry Investment Fund, aimed at expanding operations and accelerating market layout [1] - The company has previously secured nearly 100 million RMB in investments from various capital firms and recently completed a multi-million A+ round financing from Nine安 Medical [1] - Founded in 2019, Chromai specializes in the research and industrialization of high-end liquid chromatography, achieving full independent research and development of ultra-high-performance liquid chromatography (UHPLC) systems [1][2] Company Developments - Chromai's Frontier series UHPLC system features a design capable of withstanding pressures of 22,000 PSI, enhancing both separation speed and detection sensitivity [2] - The product matrix includes the Leaps series, which focuses on practical efficiency and cost-effectiveness, and has led to significant sales growth [2] - The company has developed the EyouLab intelligent chromatography data management system, integrating AI algorithms for compliance with industry standards [2] Market Position and Strategy - Chromai is addressing specific industry needs with customized solutions, such as a two-dimensional preparation solution for the biopharmaceutical sector and an automated online SPE liquid chromatography system for environmental monitoring [3] - The company officially launched commercial operations in 2023, with its products and services now available in over 20 countries, and overseas revenue steadily increasing as a percentage of total revenue [3] Leadership and Investment - The CEO of Chromai emphasizes the commitment to high-end liquid chromatography and the importance of continuous technological innovation and market recognition [4] - The Beijing Pharmaceutical and Health Industry Investment Fund focuses on supporting high-growth companies with core technological advantages in key sectors like biomedicine and high-end medical devices [5]